Ney Carter Borges: Effectiveness and Safety of Andexanet alfa in Life-Threatening Factor Xa Inhibitor-Associated Bleeding
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn about a recent article by Kei Sakamoto et al. published in JACC Asia:
“In this real-world postmarketing surveillance study evaluated the use of andexanet alfa, a specific reversal agent for factor Xa inhibitors (FXaIs), in patients presenting with life-threatening or uncontrolled bleeding.
A total of 365 Japanese patients were included, with a median age of 80 years, representing a high-risk, elderly population frequently encountered in clinical practice.
Bleeding profile
The majority of cases involved intracranial hemorrhage (71.5%), followed by gastrointestinal bleeding, highlighting the severity of presentations treated with andexanet alfa.
Effectiveness
- 80.9% of patients achieved ‘effective’ or ‘excellent’ hemostasis
- 30-day survival rate: 83.5% (95% CI: 77.4%–88.0%)
These findings demonstrate robust hemostatic efficacy in a critically ill population
Safety profile
- Adverse drug reactions: 17.5%
- Thrombotic events: 8.8% (notably cerebral infarction)
- Rebleeding events: 1.4%
Notably, more than half of adverse events occurred within the first 72 hours, emphasizing the need for close early monitoring.
Clinical interpretation
Andexanet alfa provides rapid reversal of anticoagulation, enabling effective bleeding control.
However, the associated prothrombotic risk requires careful patient selection and thoughtful timing of anticoagulation resumption.
Conclusion
Andexanet alfa is a clinically effective and essential therapeutic option for FXaI-associated major bleeding, with an acceptable safety profile when used under strict monitoring in high-risk patients.”
Title: Andexanet Alfa for Life-Threatening Bleeding Following Factor Xa Inhibitor Treatment: Postmarketing Surveillance Study in Japan
Authors: Kei Sakamoto, Miyo Ishihara, Hiroko Kato, Hyosung Kim, Masaki Okuda, Shunsuke Hiroki, Masatoshi Koga, Kazunori Toyoda
Read the Full Article on JACC Asia
More posts featuring Ney Carter Borges on Hemostasis Today.
-
May 24, 2026, 17:48Flora Peyvandi: Crucial Role of Placental ADAMTS13 in Perinatal Survival
-
May 24, 2026, 17:13Mahtab Mashayekhi: The Evolving Role of Red Blood Cell Exchange in the Management of SCD
-
May 24, 2026, 17:12Silvina Graña: Helping Families Better Understand Hemophilia and Daily Life With Bleeding Disorders
-
May 24, 2026, 17:11Miikka Vikkula: Key Insights from the ISSVA 2026 World Congress
-
May 24, 2026, 17:10Mathieu Jackson: Proud to Be Present at This Historic Moment for the Global Bleeding Disorders Community
-
May 24, 2026, 17:09Ramina Fazeli: Highlighting the Emerging Role of Neutrophil Extracellular Traps in Ovarian Cancer
-
May 24, 2026, 16:12William Wallace: Normal B12 Levels May Still Cause Brain Damage and Cognitive Decline
-
May 24, 2026, 15:54Marc Carrier: Ottawa Race Weekend Raised Over 7,000 USD for Thrombosis Canada
-
May 24, 2026, 15:44Janak Sadhu: Building a Stroke-Free Mehsana Through Community Awareness and Healthcare Collaboration